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Epigenetic alterations in the 11p15.5 imprinted gene cluster are frequent in human cancers and are associated with disordered
imprinting of insulin-like growth factor (IGF)2 and H19. Recently, an imprinted gene cluster at 14q32 has been defined and includes
two closely linked but reciprocally imprinted genes, DLK1 and GTL2, that have similarities to IGF2 and H19, respectively. Both GTL2
and H19 are maternally expressed RNAs with no protein product and display paternal allele promoter region methylation, and DLK1
and IGF2 are both paternally expressed. To determine whether methylation alterations within the 14q32 imprinted domain occur in
human tumorigenesis, we investigated the status of the GTL2 promoter differentially methylated region (DMR) in 20 neuroblastoma
tumours, 20 phaeochromocytomas and, 40 Wilms’ tumours. Hypermethylation of the GTL2 promoter DMR was detected in 25% of
neuroblastomas, 10% of phaeochromocytoma and 2.5% of Wilms’ tumours. Tumours with GTL2 promoter DMR hypermethylation
also demonstrated hypermethylation at an upstream intergenic DMR thought to represent a germline imprinting control element.
Analysis of neuroblastoma cell lines revealed that GTL2 DMR hypermethylation was associated with transcriptional repression of
GTL2. These epigenetic findings are similar to those reported in Wilms’ tumours in which H19 repression and DMR hypermethylation
is associated with loss of imprinting (LOI, biallelic expression) of IGF2. However, a neuroblastoma cell line with hypermethylation of
the GTL2 promoter and intergenic DMR did not show LOI of DLK1 and although treatment with a demethylating agent restored
GTL2 expression and reduced DLK1 expression. As described for IGF2/H19, epigenetic changes at DLK1/GTL2 occur in human
cancers. However, these changes are not associated with DLK1 LOI highlighting differences in the imprinting control mechanisms
operating in the IGF2-H19 and DLK1-GTL2 domains. GTL2 promoter and intergenic DMR hypermethylation is associated with the
loss of GTL2 expression and this may contribute to tumorigenesis in a subset of human cancers.
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Genomic imprinting is a process whereby imprinted genes
demonstrate parent-of-origin differences in allelic expression.
Although only a minority of genes are imprinted, many of those
identified to date have a role in the regulation of cell growth and
differentiation and aberrant imprinting frequently leads to
abnormal pre- and/or postnatal growth (Reik and Walter, 2001).
Furthermore, disordered imprinting has been implicated in the
pathogenesis of paediatric and adult cancers. Imprinted genes
frequently occur in clusters. In particular, the imprinted gene
cluster at 11p15.5, which contains the paternally expressed insulin-
like growth factor (IGF)2 and the maternally expressed CDKN1C
and H19 genes has been implicated in disorders of growth and in
neoplasia (Maher and Reik, 2000; Feinberg et al, 2002). For
example, germline-inactivating mutations in CDKN1C and epi-
genetic alterations leading to the loss of imprinting (LOI) (biallelic
expression) of IGF2 and silencing of CDKN1C or H19 cause
Beckwith–Wiedemann syndrome, a congenital overgrowth dis-
order associated with susceptibility to embryonal tumours (Maher
and Reik, 2000; Weksberg et al, 2003). In addition, epigenetic
alterations at IGF2 and H19 have been implicated in the
pathogenesis of sporadic childhood (e.g. Wilms’ tumour) and
adult (e.g. colorectal) cancers (Cui et al, 2001; Nakagawa et al,
2001). IGF2 and H19 are closely linked and reciprocally imprinted,
and epigenetic alterations in human cancers at an intergenic
differentially methylated region (DMR) are associated with LOI of
IGF2 and silencing at H19.
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15q13 (Prader-Willi and Angelman syndrome region) have been
the subject of intense investigation. Recently, an imprinted gene
cluster at 14q32 (distal mouse chromosome 12) was identified. The
first imprinted 14q32 gene identified was GTL2/Gtl2, which, like
H19, is a maternally expressed RNA with no apparent open reading
frame (Miyoshi et al, 2000). Subsequently, a paternally expressed
gene, DLK1/Dlk1, which encodes an EGF-like membrane protein
similar to the Drosophila Delta gene was identified upstream of
GTL/Gtl2 (Kobayashi et al, 2000; Schmidt et al, 2000; Takada et al,
2000; Wylie et al, 2000). There are a number of similarities between
the IGF2/H19 and the DLK1/GTL2 domains. In both cases, two
closely linked genes are similarly organised, reciprocally imprinted
and developmentally regulated; H19 and GTL2 do not encode
known proteins, and paternally methylated DMRs associated with
both genes have been implicated in the regulation of their
imprinting (Paulsen et al, 2001; Takada et al, 2002).
In sheep, a single-nucleotide (nt) substitution is associated with
altered postnatal expression of GTL2 and DLK1, although their
imprinting is not perturbed. This mutation results in the Callipyge
muscle hypertrophy phenotype (Charlier et al, 2001; Freking et al,
2002; Georges et al, 2003). In human mutations or epigenetic
alterations of DLK1 and GTL2 have not been described, although
distinct phenotypes associated with maternal and paternal disomy
for chromosome 14 are reported (Georgiades et al, 2000;
Eggermann et al, 2001; Kurosawa et al, 2002). SAGE analysis
demonstrated high expression of DLK1 in a subset of neuroblas-
toma (van Limpt et al, 2000), but a follow-up study did not find
any genetic alterations (e.g. mutation, duplication or rearrange-
ment) or LOI in neuroblastomas with DLK1 overexpression (van
Limpt et al, 2003). In addition, downregulation of GTL2 has been
reported in pituitary adenomas with ectopic expression of GTL2
inhibiting tumour growth in vitro, suggesting a tumour suppressor
function for that gene (Zhang et al, 2003).
We have investigated neuroblastoma and other tumours to
determine whether epigenetic alterations within the DLK1-GTL2
imprinted domain are a feature of human neoplasia. We
investigated neuroblastoma and phaeochromocytoma as DLK1 is
highly expressed in the adrenal medulla. Neuroblastoma may also
demonstrate 14q allele loss and Wilms’ tumour was of interest as
epigenetic alterations at the IGF2/H19 locus are common in this
tumour.
MATERIALS AND METHODS
Multiplex methylation polymerase chain reaction (mPCR)
assay
Methylation-specific PCR with oligonucleotide primers specific for
the methylated and unmethylated copies of the GTL2 promoter on
chromosome 14q32 were performed using previously published
primers (Murphy et al, 2003): MSM-UF (50-GAG GAT GGT TAG
TTA TTG GGG T-30; nt position 65912 (GenBank accession no.
AL117190)); MSM-UR (50-CCA CCA TAA CCA ACA CCC TAT
AAT CAC A-30; nt 65931–66004); MSM-MF (50-GTT AGT AAT
CGG GTT TGT CGG C-30; nt 64450–64471) and MSM-MR (50-AAT
CAT AAC TCC GAA CAC CCG CG-30; nt 64587–64609). The
multiplex mPCR conditions used were initial denaturation at 951C
for 3min; five cycles of 951C for 30s, 701C for 30s, 721C for 30s;
five cycles of 951C for 30s, 651C for 30s, 721C for 30s; followed by
30 cycles of 951C for 30s, 601C for 30s, 721C for 30s and a final
extension of 721C for 5min. PCR amplification were performed
using 0.05Uml
 1 Taq polymerase in (NH4)2SO4 buffer with 3.0mM
MgCl2 (MBI Fermentas, St Leon-Rot, Germany). PCR products
(160bp for methylated allele and 120bp for unmethylated) were
separated on a 3% agarose gel, stained with ethidium bromide and
visualised under UV illumination.
Analysis of DNA methylation using bisulphite sequencing
Genomic DNA was treated with sodium bisulphite using pre-
viously published method (Herman et al, 1996). DNA (0.5–1mg)
was denatured at 371C for 10min in 0.3 M NaOH followed by
sulphonation of unmethylated cytosines by incubation in 3.12 M
sodium bisulphite containing 1 M hydroquinone (pH 5) at 951C for
30s and 501C for 15min for 20 cycles. The resulting sulphonated
DNA was purified using the Wizard DNA clean-up system
(Promega, Southampton, UK) according to the manufacturer’s
instructions and DNA was eluted with 50ml of distilled water.
Following elution, DNA was desulphonated in 0.3 M NaOH for
5min at room temperature, ethanol precipitated and resuspended
in 50ml distilled water.
Methylation status of GTL2 and DLK1 DMRs
Following multiplex PCR methylation screening (see above), the
methylation status of three areas of the CpG-rich region upstream
of GTL2 were analysed in detail (G1, position 65897–66197; G2,
position 66541–66920; G3, position 67541–67910; GeneBank
accession no. AL117190; relative to GTL2 transcription start site,
G1¼ 363bp- 161bp upstream; G2¼þ293bp-þ673bp
downstream; G3¼þ1213bp-þ1583bp downstream GTL2 trans-
cription start site; GeneBank accession no. AY314975) and a region
upstream DLK1 promoter (D1, position 140551–140810; Gene-
Bank accession no. AL132711) and two downstream regions (D2,
position 141271–141420; D3, position 141571–141894; GeneBank
accession no. AL132711). Except for D1 and D2 regions,
bisulphite-modified DNA was amplified using two rounds of
nested PCR (951C for 15min followed by 35 cycles of 951C for 30s,
55–581C for 30s, 721C for 30s and a final extension of 721C for
5min) using HotStar Taq DNA polymerase (Qiagen, Crawley,
UK). Primer sets were designed to amplify DNA fragments
containing both methylated and unmethylated CpG dinucleotides.
The primer sequences are: G1F (50-TTA GGT GTG GGA TTT GYG
TTT YGA TAG TT-30); G1R (50-CAA AAA AAA TAA TCT CTA
ACR TCA ACR CAT TCT ACT A-30); G1FN (50-GGT TAT TGG
TYG TTT GAG GAY GGT TAG TT-30); G2F (50-TTA GGG TTT TTT
TTT GGA GGG TTT AGT-30); G2R (50-AAA ACT AAT CCA TAA
AAA CTA CTA ACA AAT-30); G2RN (50-ACC TAA AAT CCA CAC
TAC ACT AAA CCT ATA-30); G3F (50-AGA GGG AAT AGT TTT
GAG ATT TTT YGG ATT TAT-30); G3R (50-ATC CTC CAA ACA
CCR CTA TCA CRC ATA TAA-30); G3RN (50-ATA ATC TCR AAA
CRA AAA ACA AAA CCT ATA-30); D1F (50-TAT ATA GTG GGT
ATT TTA ATT GTT TTT TAT-30); D1R (50-TAA AAA AAC AAA
CCC ATA AAC ATC CCC AAA-30); D2F (50-TTG GTA ATT AGT
ATT TTT TAT TTT TA-30); D2R (50-ACT TTT ATC ACA AAT AAC
ATA CAT AAA C-30); D3F (50-TTG TTT ATG TAT GTT ATT GTG
GAT-30); D3R (50-TAA AAT CCC RAA CAC ACR TAC AAT AAT-
30); D3FN (50-GTT AAG GTT TTG ATT GAG ATG TTG TGT G-30);
and D3RN (50-TAT ACC CCT AAC CAT AAA AAC RCA AA-30).
Amplification products were purified from agarose gel using
QiaQuick gel extraction kit (Qiagen, Crawley, UK), cloned into
pGem T-Easy vector system (Promega, Southampton, UK). In all,
eight to 10 individual clones for each DMR regions were sequenced
using BigDye terminator cycle sequencing kit V 1.1/3.1 (Perkin-
Elmer/Applied Biosystems, Warrington, UK) and run on an
ABI377/3730.
Methylation status of the intergenic germline-derived
differentially methylated region (IG-DMR)
A seminested PCR was performed to amplify the IG-DMR (nt
position 51021–51180; GeneBank accession no. AL117190). The
primer sequences are: IG-F (50-TTT TGA GGA GAT TGA TAT TTT
TAG TTT TAT T-30); IG-R (50-ATA AAC TAC ACT ACT AAA AAC
TAC ATT TAA A-30); and IG-Fnes (50-TTA GGT TGG AAT TGT
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described using HotStar Taq DNA polymerase (Qiagen) with an
annealing temperature of 531C and 1.5mM MgCl2 for both first-
round (primer set IG-F/IG-R) and second-round (primer set IG-
Fnes/IG-R) PCRs. PCR products were then cloned and sequenced
as described above.
Expression analysis: reverse transcriptase (RT) and
quantitative real-time PCR
RNA (1mg) was reverse transcribed using Reverse Transcription
Systems and oligo-dT primers (Promega) according to the
manufacturer’s protocols. cDNA (1ml) obtained was then used as
template for RT–PCR amplification. A single-nucleotide poly-
morphism (SNP) previously identified in exon 5 of GTL2 and an
SNP in exon 5 of DLK1 (Wylie et al, 2000) were used to analyse
GTL2 and DLK1 gene expression. GTL2 and DLK1 cDNA were
amplified using oligonucleotide primers described by Wylie et al
(2000), except that for GTL2 reverse primer, GTL2RK (50-TTC CAC
GGA GTA GAG CGA GTC A-30), was used. Amplification products
were purified and sequenced as described above using primers:
GTL2FS (50-ATC CCT TTG GGA AAT TCT CAG G-30) and DLK1FS
(50-AGG CAC CTG CGT GGA TGA T-30). For quantitative real-time
PCR, total RNA from cell lines was extracted with the RNAzol B
(Biogenesis, Poole, UK) according to the manufacturer’s instruc-
tion and treated with DNAse 1 (Invitrogen, Paisley, UK). Total
RNA (1mg) was reverse transcribed as described previously. The
cDNA was used in triplicate in a real-time PCR analysis using a
real-time Thermal Cycler Model 7900 (Applied Biosystems). The
primer sets are: DLK1 (50-GCG AGG ATG ACA ATG TTT GC-30
(forward) and 50-AGC AGG CCC GAA CAT CTC TA-30 (reverse))
and GTL2 (50-ATC AGC CAA GCT TCT TGG AA-30 (forward) and
50-AGC TTC CAT CCG CAG TTC T-30 (reverse)). Beta-actin was
used as a control for normalisation. PCR was performed in a 25ml
volume that included 12.5mlo f2   Cyber green (Applied
Biosystems), 25ng of cDNA template and 0.0125–0.025pmol of
each primer. Relative RNA quantification was performed using the
comparative CT method. The fold differences in RNA expression
are the mean value from three independent observations.
Treatment of cell lines with 5-aza-20-deoxycytidine
(5-aza-dC)
5-Aza-dC (Sigma, Gillingham, Dorset, UK) was freshly prepared in
ddH2O at 2mgml
 1 and filter sterilised. A total of 1 10
6 cells
were plated in 75cm
2 flask in RPMI 1640 medium supplemented
with 10% FCS and left to settle for 24h (day 0). Cells were treated
with 2mM of 5-aza-dC at day 1 and 4 and harvested at day 5. The
culture medium was changed before each treatment and 24h after
treatment.
RESULTS
Epigenetic analysis of DLK1/GTL2 domain in
neuroblastoma tumours and cell lines
The methylation status of the GTL2 promoter DMR was assessed in
four normal control blood DNA samples and all four cases
demonstrated both methylated and unmethylated allele products.
We then analysed tumour DNA from 20 primary neuroblastomas.
We found that five of 20 (25%) neuroblastoma tumours
demonstrated only products from a methylated allele at the
GTL2 promoter DMR. The other 15 tumours showed a normal
result with methylated and unmethylated allele products. In four of
five tumours with hypermethylation of the GTL2 promoter DMR,
heterozygosity at a DLK1 SNP (c.564T4C) (n¼ 2) or at closely
linked microsatellite markers (D14S598, D14S1426, D14S749 and
D14S1006) excluded 14q32 maternal allele loss as a cause of the
GTL2 promoter DMR hypermethylation.
In order to investigate whether GTL2 promoter DMR hyper-
methylation in tumours was associated with alterations in DLK and
GTL2 expression and imprinting, we examined the GTL2 promoter
DMR methylation status in four neuroblastoma cell lines (SK-N-
F1, SK-N-AS, SK-N-DZ, Kelly). All four neuroblastoma cell lines
demonstrated GTL2 promoter DMR hypermethylation (Figure 1A
and B). One cell line, SK-N-AS, was heterozygous for a transcribed
DLK1 SNP, thus enabling us to (a) exclude maternal allele loss as
the cause of 50 GTL2 DMR hypermethylation and (b) perform
allele-specific expression studies to investigate DLK1 imprinting
status. We also analysed DLK1 and GTL2 expression before and
after treatment with the demethylating agent 5-azacytidine (5-
AzaC) in the four neuroblastoma cell lines with GTL2 promoter
DMR hypermethylation. In all cases, there was silencing of GTL2
expression in the untreated cell line and reactivation of GTL2
expression after treatment with 5-AzaC (Figure 1C and Table 1). In
addition, 5-AzaC treatment resulted in a reduction in DLK1 mRNA
expression. Analysis of DLK1 allelic expression in the informative
SK-N-AS neuroblastoma line demonstrated monoallelic (allele C)
DLK1 expression pre- and post-treatment with 5-AzaC (Figure 2).
Thus, hypermethylation of the GTL2 promoter DMR in the SK-N-AS
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Figure 1 (A) Methylation-specific multiplexed PCR of the DMR upstream GTL2 promoter in neuroblastoma cell lines showing the presence of only
methylated allele of 160bp. Mþ is in vitro methylated DNA. (B) Normal blood DNA was used as control showing both unmethylated (120bp) and
methylated (160bp) allele. (C) RT–PCR analysis of DLK1 and GTL2 in four neuroblastoma cell lines before ( ) and after (þ) treatment with demethylating
agent 5-AzaC. DLK1 expression was reduced, while GTL2 expression was activated following 5-AzaC treatment. Molecular weight marker was a 100-bp
ladder (Invitrogen).
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silencing of GTL2 expression, but not LOI of DLK1.
Hypermethylation of 50 GTL2 promoter was observed in five of
20 (25%) of neuroblastoma tumours. RNA was available from
seven of the 20 tumours (see Figure 3). A low level of GTL2
expression was detected in the tumour with hypermethylation of
the 50 GTL2 promoter DMR (possibly caused by normal tissue
contamination).
To establish the precise epigenetic status of individual CpGs
within the GTL2 promoter DMR region, bisulphite sequencing was
undertaken in four normal control blood DNA samples and in the
SK-N-AS hypermethylated neuroblastoma cell line, which is
heterozygous for DLK1 SNP. A total of 54 CpGs were analysed in
three subregions of the CpG-rich region upstream of GTL2 (G1
n¼12 CpGs, G2 n¼19 and G3 n¼21). Between eight and 10
clones were sequenced from each of the normal blood samples and
the methylation status of each of the 54 CpGs determined (see
Figure 4C). Comparison of the CpG methylation status of the GTL2
promoter DMR subregions in controls and the neuroblastoma cell
line revealed that within subregions G1 and G2, there was extensive
methylation of CpGs in SK-N-AS compared to normal control
DNAs. However, in subregion G3, there was little difference
between the CpG methylation status of normal control DNAs and
the SK-N-AS cell line DNA.
Methylation analysis of the GTL2 promoter DMR in
phaeochromocytoma and Wilms’ tumour
Methylation analysis of the GTL2 DMR was then undertaken in 20
phaeochromocytomas and 40 Wilms’ tumours. GTL2 promoter
DMR hypermethylation was detected in two phaeochromocytomas
(10%) and one Wilms’ tumour (2.5%). Genotyping with 14q32
microsatellite markers (D14S598, D14S1426, D14S1006, D14S749)
excluded 14q32 allele loss in all three tumours.
Methylation analysis of IG-DMR
Recently, an IG-DMR was demonstrated to function as an
imprinting control element for all imprinted genes on the maternal
chromosome only (Lin et al, 2003). To determine whether GTL2
promoter DMR hypermethylation was associated with epigenetic
alterations at the upstream IG-DMR, we analysed the methylation
status of the eight CpGs within the IG-DMR in four normal control
DNAs and in four neuroblastoma cell lines with 50 GTL2 DMR
methylation. Eight to 12 individual clones for each were analysed
for IG-DMR CpGs methylation status. In the four normal control
samples, 32% of IG-DMR CpGs sequenced were methylated, while
in the SK-N-AS neuroblastoma cell line with GTL2 promoter DMR
hypermethylation, all eight CpGs (n¼12 clones) were methylated.
In addition, the three neuroblastoma cell lines with 50 GTL2 DMR
hypermethylation (but uninformative for DLK1 imprinting status)
showed almost complete methylation at all IG-DMR CpGs analysed
(see Figure 4B). Similarly, analysis of the IG-DMR CpG methyla-
tion status in four primary tumours (two neuroblastoma, one
phaeochromocytoma and one Wilms’ tumour) with GTL2
promoter DMR hypermethylation demonstrated heavy CpG
methylation (although less complete than in the neuroblastoma
cell lines, possibly because of normal tissue contamination). In
contrast, cell lines and tumours with GTL2 promoter DMR and IG-
DMR hypermethylation did not show any differences from normal
controls at the CpG-rich region upstream of the DLK1 promoter
nor at the two CpG-rich regions downstream of the DLK1
promoter.
DISCUSSION
We detected epigenetic changes within the GTL2 promoter DMR
(and the IG-DMR) in 25% of neuroblastoma tumours, 10% of
phaeochromocytoma and 2.5% of Wilms’ tumours analysed. In
most cases, allele loss was excluded as a cause of the apparent
hypermethylation. All cases with GTL2 promoter DMR methyla-
tion also demonstrated hypermethylation at the upstream IG-DMR
region, but epigenetic alterations were not detected in the three
Table 1 DLK1 and GTL2 expression in neuroblastoma cell lines following
5-AzaC treatment analysed by real-time PCR
Cell line
DLK1
Fold change (7s.d.)
a
after 5-AzaC
treatment
GTL2
Fold change (7s.d.)
a
after 5-AzaC
treatment
SK-N-DZ 0.28270.056 5.43772.037
SK-N-AS 0.21970.097 3.95370.724
SK-N-F1 0.36570.259 2.77370.570
Kelly 0.17370.015 2.69370.825
5-AzaC¼5-azacytidine; PCR¼polymerase chain reaction; s.d.¼standard deviation.
aThe fold differences in RNA expression are the mean7s.d. of three independent
observations.
Genomic
T/C
5-AzaC pretreatment
C/C
5-AzaC post-treatment
C/C
Figure 2 Analysis of DLK1 allele expression in the informative SK-N-AS
cell line. DLK1 is monoallelically expressed before and following treatment
with 5-AzaC.
GTL2
GAPDH
1234 67 8 5
Figure 3 RT–PCR showing GTL2 expression in neuroblastoma tumours
without gain of methylation at 50 GTL2 DMRs (lanes 1–6) and tumour with
gain of methylation at 50 GTL2 DMRs (lane 7). Low level of GTL2 expression
in this tumour may be caused by normal tissue contamination. Lane 8 is a
negative control and GAPDH was used as unlinked control gene.
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expression in four neuroblastoma cell lines with GTL2 DMR
hypermethylation demonstrated repression of GTL2 transcription
and re-expression of GTL2 after treatment with 5-AzaC. In most
cell lines, re-expression of GTL2 after treatment with 5-AzaC was
associated with downregulation of DLK1 expression. Furthermore,
in an informative neuroblastoma cell line (SK-N-AS), there was no
evidence of LOI of DLK1. The absence of LOI of DLK1 is consistent
with other reports of monoallelic DLK1 expression in neuroblas-
toma, brain tumours and lymphoma (van Limpt et al, 2003; Yin
et al, 2004). The DLK1/GTL2 imprinted domain has similarities to
the IGF2/H19 gene at 11p15.5. In both cases, two closely linked
genes are reciprocally imprinted, and both H19 and GTL2 do not
appear to encode a protein. Like H19 and Igf2, Gtl2 and Dlk
transcripts can be found in the same tissues during development
(Takada et al, 2000). In Beckwith–Wiedemann syndrome and
sporadic Wilms’ tumour, hypermethylation of the H19 promoter
DMR (and the upstream ‘CTCF box’ DMR) is associated with
silencing of H19 expression (Cui et al, 2001; Nakagawa et al, 2001).
We identified hypermethylation of the GTL2 DMRs in tumours
and cell lines, so there are apparent similarities between
epigenetics at the H19 and GTL2 loci in human neoplasia, although
the frequency of GTL2 hypermethylation in Wilms’ tumour is
much less than that at H19. However, whereas de novo
hypermethylation of the H19 promoter and CTCF box DMRs is
associated with H19 silencing and LOI of IGF2, LOI of DLK1 was
not associated with GTL2 promoter DMR and IG-DMR hyper-
methylation. In mice, deletion of the unmethylated copy of the
IG-DMR leads to bidirectional LOI of all genes in the imprinted
cluster after maternal inheritance, but imprinting is unaltered after
paternal transmission of the deleted methylated copy (Lin et al,
2003). This asymmetric regulation of imprinting distinguishes the
imprinting control mechanisms in the 11p15.5 and the 14q32
imprinted gene clusters. The Callipyge phenotype demonstrates
complex inheritance patterns. Thus, while paternal inheritance of
the Callipyge mutation is associated with muscle hypertrophy, and
maternal transmission is not, surprisingly, homozygotes do not
demonstrate the phenotype. This unusual inheritance pattern
(known as polar overdominance) has been attributed to the
Callipyge mutation affecting a long-range control element resulting
in enhanced expression in cis of all genes in the heterozygote sheep
(but with no change in their imprinting) (Charlier et al, 2001;
Freking et al, 2002; Georges et al, 2003). Furthermore, the absence
of a mutant phenotype in the homozygotes suggests that
overexpression of imprinted genes on the maternal chromosome
abrogates the functional defect caused by the paternal chromo-
some in trans. Hence, when the Callipyge mutation is paternally
inherited, DLK1 transcription is upregulated, while GTL2 is
upregulated after maternal transmission (Charlier et al, 2001;
Freking et al, 2002; Georges et al, 2003). In homozygotes, it is
postulated that GTL2-associated transcripts negatively regulate
DLK1 transcripts; however, the precise mechanism is not known.
Our finding that hypermethylation of the GTL2 promoter and
upstream DMR is associated with silencing of GTL2 and
upregulation of DLK1 without LOI would be consistent with a
model, whereby GTL2-associated transcripts negatively regulate
DLK1 transcription and further analysis of neuroblastoma cell
lines with GTL2 hypermethylation and silencing may provide
important insights into the mechanisms of imprinting control in
the 14q32 imprinted domain.
DLK1 encodes a transmembrane protein with six EGF-like
repeats that shows homology to the Delta gene in Drosophila
melanogaster, which is involved in the Notch signalling pathway.
The precise function of the DLK1 protein is unclear, but DLK1
expression is upregulated in myelodysplastic syndrome, a slowly
progressing haematological malignancy, and in uterine leiomyomata
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Figure 4 (A) Schematic representation of GTL2 and IG-DMRs in human showing the position of regions analysed: G1¼ 363bp- 161bp upstream,
G2¼þ293bp-þ673bp downstream, and G3¼þ1213bp-þ1583bp downstream of GTL2 transcription start site, GeneBank accession no.
AY314975; IG-DMR¼nt 51021–51180, GeneBank accession no. AL 117190). (B) Methylation status of the CpGs in the IG-DMR in the normal blood,
neuroblastoma cell lines, a Wilms’ tumour, two neuroblastoma tumours and a phaeochromocytoma tumour with gain of methylation at the 50 GTL2 DMRs.
(C) Methylation status of GTL2 DMRs in neuroblastoma cell lines. The methylation status is shown in circles. Open and filled circles indicates complete
unmethylation and full methylation, respectively. Partially filled circles indicate the degree of partial methylation.
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s(compared to normal myometrium) (Miyazato et al, 2001; Tsibris
et al, 2002). In addition, overexpression of the DLK1 protein is
reported to prevent adipocyte differentiation of 3T3-L1 cells in
response to IGF1 or insulin. These latter effects were attributed to
changes in the activation levels and kinetics of extracellular-
regulated kinase/mitogen-activated protein kinase (Ruiz-Hidalgo
et al, 2002). However, although it might be postulated that
increased DLK1 expression might be pro-oncogenic, there is no
direct evidence for this. Indeed, van Limpt et al (2003) suggested
that neuroblastomas DLK1 expression increases during chromaffin
cell lineage differentiation and high DLK1 expression in neuro-
blastoma cell lines may merely indicate that the neuroblastoma has
developed from a later stage chromaffin cell precursor. Hence,
upregulation of DLK1 expression associated with GTL2 promoter
and intergenic DMR hypermethylation may be coincidental to
tumorigenesis. GTL2 promoter and intergenic DMR hypermethy-
lation was associated with transcriptional silencing of GTL2 and
treatment with 5-AzaC resulted in re-expression of GTL2. Recently,
an isoform of GTL2, MEG3a, was reported to be expressed highly
in normal pituitary and brain and in other tissues including
adrenal (Zhang et al, 2003), but not in many pituitary tumours.
Furthermore, transfection of MEG3a into a HeLa cell line inhibited
cell proliferation in the in vitro colony formation and growth rate
assays. Hence, although neither GTL2 nor MEG3a have been
shown to encode an expressed protein, GTL2 promoter and
intergenic DMR hypermethylation might promote tumorigenesis
by downregulating GTL2 expression. These findings are similar to
those reported for H19 (Hao et al, 1993), although the precise role
of H19 silencing per se in Wilms’ tumour and tumour suscept-
ibility in Beckwith–Wiedemann syndrome has not been unequi-
vocally established (Tycko, 2000). Thus, further investigations of
the potential roles of GTL2, MEG3a and epigenetic changes in the
DLK1/GTL2 domain are indicated.
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